Q-omics provides the consensus-scored MIR186 profile across patient tissues and cancer cell-line models. MIR186 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MIR186 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MIR186 RNA expression shows 20,402 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, COAD, and THYM as cancer lineages where MIR186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR186 survival associations across molecular data types. MIR186 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR186 RNA expression–survival associations across cancer types. High MIR186 expression shows unfavorable associations in LGG, THCA and UVM, but favorable associations in HNSC, SKCM and READ. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MIR186 RNA expression.
This table summarizes MIR186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR186 shows lower tumor expression in COAD, LUSC, UCEC, BRCA and LUAD and higher tumor expression in CHOL. The COAD box plot shows higher MIR186 RNA expression in normal versus tumor tissue (log2 FC = −1.100, t-test p < 0.001).
This table shows molecular features associated with MIR186 in patient tissues and cancer cell lines. In patient samples, MIR186 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
